Suppressing CD33 stimulates phagocytosis, slows plaque growth. A protective CD33 mutation could be a gain of function that activates phagocytosis. The CD33 receptor acts as a dimer. At the 14th ...

Acute myeloid leukemia (AML) is one of the most common forms of cancer in children and adults. CD33, a protein often expressed on the surface of leukemic cells, has been a long-standing target for AML ...

Researchers have tested a gene-edited stem cell transplant designed to shield healthy blood-forming cells from powerful ...

This first-in-class ASO replicates the protective effects of naturally occurring CD33 loss-of-function variants, which are associated with increased resilience to neurodegenerative disease, reduced ...

A multicentre clinical trial led by Washington University School of Medicine in St Louis has shown that donor stem cells ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced an exclusive licensing ...

Antibody-based therapeutics are valuable tools for the treatment of many human diseases. For example, antibody-based immunotherapies targeting the leukemia antigens CD19 and CD20 have been remarkably ...

SAN FRANCISCO, CA--(Marketwired - Aug 10, 2016) - Amphivena Therapeutics, Inc., a developer of cancer immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted an ...

Aggressive blood cancers such as acute myeloid leukemia and myelodysplastic syndrome remain among the hardest cancers to ...